Dynavax Technologies
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
Domain
dynavax.com
Country
United StatesIndustry
BiopharmaEmployees
251-500
Last Funding
$225.0M
Founded
1995
Tech Stack (7 technologies)
Frequently Asked Questions
What technologies does Dynavax Technologies use?+
Dynavax Technologies uses 7 technologies including Google Analytics, OneTrust, Google Tag Manager.
What industry is Dynavax Technologies in?+
Dynavax Technologies operates in the Biopharma industry.
Where is Dynavax Technologies based?+
Dynavax Technologies is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026